This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Name: GDC-6036
Sequential Assignment
There is one SNP
A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation. --- G12C ---
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. --- G12C ---
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. --- G12C --- --- G12C ---
Inclusion Criteria: - Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation. --- G12C ---
Exclusion Criteria: - Active brain metastases - Malabsorption or other condition that interferes with enteral absorption - Clinically significant cardiovascular dysfunction or liver disease Inclusion Criteria: - Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation. --- G12C ---